menu
    • menu
    [{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cimeio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CD117-shielded Cell","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cimeio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cimeio Therapeutics"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Genetic Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Prime Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Prime Medicine \/ Prime Medicine"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"14","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by Prime Medicine

    Menu

    Prime Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

                            Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BMS Pays Prime $110M to Form T-cell Therapy Pact

                            Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $110.0 million

                            September 30, 2024

                            Lead Product(s) : T-Cell-based Therapy

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prime Medicine Gets FDA Clearance for IND Application Of PM359

                            Details : PM359 is Prime Medicine’s candidate for chronic granulomatous disease (CGD), targeting the p47phox variant in this serious childhood condition.

                            Brand Name : PM359

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 29, 2024

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : $161.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prime Medicine Closes Upsized Public Offering with Underwriters' Option Exercise

                            Details : Proceeds will fund PM359 development, utilizing prime editing technology on autologous hematopoietic stem cells as a potential treatment for chronic granulomatous disease.

                            Brand Name : PM359

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 20, 2024

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : $161.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prime Medicine Announces Proposed Public Offering of Common Stock

                            Details : Proceeds will fund PM359 development, using prime editing to modify autologous hematopoietic stem cells as a potential treatment for chronic granulomatous disease.

                            Brand Name : PM359

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : PM359

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : J.P. Morgan

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation

                            Details : The net proceeds will be used to support the development of curative therapies by using Prime Editing to correct CFTR mutations at the natural genetic locus, for the treatment of Cystic Fibrosis (CF).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Genetic Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies...

                            Details : Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapi...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Genetic Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD117-shielded Cell

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cimeio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell &...

                            Details : Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : CD117-shielded Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cimeio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : J.P. Morgan

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prime Medicine Announces Closing of Upsized Initial Public Offering

                            Details : Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : J.P. Morgan

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Undisclosed

                            Sponsor : J.P. Morgan

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prime Medicine Announces Pricing of Upsized Initial Public Offering

                            Details : Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Undisclosed

                            Sponsor : J.P. Morgan

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth